anticorps DUBA, anticorps AA407879, anticorps AI553596, anticorps BB114028, anticorps DXImx46e, anticorps Sfc7, anticorps otud5, anticorps si:bz30i22.1, anticorps si:rp71-30i22.1, anticorps zgc:154072, anticorps wu:fi28a06, anticorps zgc:100839, anticorps OTU deubiquitinase 5, anticorps OTU domain containing 5, anticorps OTU deubiquitinase 5a, anticorps OTU deubiquitinase 5 S homeolog, anticorps OTU deubiquitinase 5 L homeolog, anticorps OTU deubiquitinase 5b, anticorps OTUD5, anticorps Otud5, anticorps otud5a, anticorps otud5.S, anticorps otud5.L, anticorps otud5b
Sujet
OTUD5 is a member of the OTU (ovarian tumor) domain-containing cysteine protease superfamily. The OTU domain confers deubiquitinase activity and OTUD5 has been shown to suppress the type I interferon (IFN-I)-dependent innate immune response by cleaving the polyubiquitin chain from TRAF3, an essential type I interferon adaptor protein. Cleavage results in disassociation of TRAF3 from a downstream signaling complex containing TBK1 and the disruption of the IFN-I signaling cascade, indicating that OTUD5 acts as a negative regulator of innate immune responses. It has been suggested that by suppressing IFN-I production, OTUD5 may function to inhibit the emergence of certain autoimmune disorders such as systemic lupus erythematosus. Multiple isoforms of OTUD5 are known to exist.Synonyms: DUBA, Deubiquitinating enzyme A, OTU domain-containing protein 5